Additionally, the detection of a TFG::ROS1 fusion in an ALK-negative inflammatory myofibroblastic tumor and the neoadjuvant use of crizotinib in that patient demonstrate the expanding relevance of targeted therapies in pediatric pulmonary malignancies. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.